신약개발 소식, 해외 논문들
FDA Clears IND for BBT-176 in Patients with EGFR-Mutant NSCLC
stayalive1
2020. 6. 9. 06:08
www.targetedonc.com/view/fda-clears-ind-for-bbt176-in-patients-with-egfrmutant-nsclc
FDA Clears IND for BBT-176 in Patients with EGFR-Mutant NSCLC
The Investigational New Drug Application for the novel EGFR tyrosine kinase inhibitor BBT-176 was cleared by the FDA for treatment of EGFR C797S–mutant non–small cell lung cancer, according to a press release from Bridge Biotherapeutics, Inc, develope
www.targetedonc.com
타그리소 저항을 치료하기 위한 또 하나의 신약.
우리나라 기사
www.biospectator.com/view/news_view.php?varAtcId=9156
브릿지바이오, 폐암 EGFR C797S 저해제 “韓·美 IND 제출”
브릿지바이오테라퓨틱스가 폐암 표적 항암제 후보물질 ‘BBT-176’의 환자 대상 임상 1/2상에 들어가기 위해 한국 식품의약품안전처와 미국 식품의약국(
www.biospectator.com